Botulinum toxin in the treatment of orofacial tardive dyskinesias: a single blind study
Completed
- Conditions
- Tardive dyskinesiaNervous System DiseasesDystonia
- Registration Number
- ISRCTN81508784
- Lead Sponsor
- Parnassia Psycho-medical Centre (Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
1. Patients suffering from orofacial tardive dyskinesias for at least 3 months
2. Stable dosage of psychopharmacological medication
3. Written informed consent by the patient
Exclusion Criteria
1. Age younger than 18 years
2. Contraindication for botulinum toxin (myasthenia gravis, Lambert Eaton Myasthenic Syndrome)
3. Women known to be pregnant or having a positive pregnancy test
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Abnormal Involuntary Movement Scale (AIMS)<br>2. The number of patients that wanted to continue the treatment with botulinum toxin after cessation of the study
- Secondary Outcome Measures
Name Time Method 1. Visual Analogue Scale <br>2. World Health Organization Quality Of Life, abbreviated version